Summary: Current treatments for Alzheimer’s disease typically rely on repeated, high-dose infusions of monoclonal antibodies to slow cognitive decline by clearing amyloid-beta protein. Researchers at Washington University School of Medicine have developed a potentially transformative alternative: CAR-astrocytes. Using a harmless viral vector to deliver a gene encoding a chimeric antigen receptor (CAR) to astrocytes—the brain’s most abundant glial cells—scientists reprogrammed these cells with a molecular “homing device” that directs them to recognize and engulf amyloid-beta plaques.
These engineered cells act like “super cleaners.” In a study published in Science, a single injection of CAR-astrocytes prevented plaque formation when given to young mice and reduced existing plaque burden by about half in older mice that already had extensive amyloid accumulation.
Key Facts
- The homing device: Astrocytes were given a Chimeric Antigen Receptor (CAR) that binds to amyloid-beta, enabling targeted capture and subsequent degradation.
- Single-dose potential: Unlike monthly antibody infusions, this approach achieved major effects from just one systemic administration in mouse models.
- Prevention and treatment: Early treatment stopped plaques from forming; treatment after plaque development reduced plaque levels by roughly 50% over three months.
- Reducing the cleanup burden: Microglia normally clear brain debris but can be overwhelmed in neurodegenerative disease. CAR-astrocytes add durable, brain-intrinsic clearance capacity.
- Adaptable platform: By changing the CAR target, the same strategy could be redirected to other brain pathologies, such as tumors, opening possibilities beyond Alzheimer’s.
Source: Washington University School of Medicine
The newest Alzheimer’s therapies that alter disease trajectory are monoclonal antibodies that reduce amyloid accumulation and extend independent living by months. However, they require frequent high-dose infusions and carry risks and logistical challenges. To create a more durable and potentially more effective approach, researchers engineered astrocytes to express CARs that direct them to phagocytose amyloid-beta.
Published March 5 in Science, the study adapted the CAR concept—widely used in oncology with CAR-T cells—to central nervous system glia. Instead of modifying T cells to attack cancer, the team delivered CAR constructs to astrocytes so these resident brain cells could identify and clear amyloid-beta aggregates that contribute to Alzheimer’s pathology.
“This research represents the first successful engineering of astrocytes to selectively target and remove amyloid-beta plaques in a mouse model of Alzheimer’s disease,” said Marco Colonna, MD, senior author and professor of pathology. The investigators caution that additional work is required to refine the approach and evaluate safety, but they emphasize the promise of CAR-astrocytes as a new immunotherapy avenue for neurodegenerative diseases and possibly brain tumors.
How CAR-astrocytes clear brain waste
Alzheimer’s disease typically begins with accumulation of amyloid-beta, a sticky protein that aggregates into extracellular plaques. Plaque accumulation triggers downstream events, including tau pathology, synaptic dysfunction, and neuronal loss. Microglia are the primary phagocytic cells in the brain, but during chronic disease they can become dysfunctional or overwhelmed.
To supplement microglial clearance, the research team converted astrocytes into amyloid-clearing cells. Graduate researcher Yun Chen designed CAR constructs that fuse an anti-amyloid single-chain antibody fragment to intracellular phagocytic signaling domains. These CAR genes were packaged into a benign adeno-associated viral vector and delivered systemically to achieve widespread central nervous system expression.
After gene delivery, astrocytes display the CAR on their surface, enabling them to bind amyloid-beta and promote engulfment and degradation. In mice genetically predisposed to develop amyloid plaques, a single systemic injection prevented plaque formation when given before plaques emerged and halved plaque burden when given to older, plaque-bearing animals.
The investigators tested multiple CAR designs and selected constructs that functioned robustly in cell culture and in vivo. Single-cell analyses and immunostaining showed that CAR expression shifted astrocytes into disease-associated states while guiding microglia toward more homeostatic profiles, reducing signatures associated with cellular exhaustion. Different CAR designs produced partially distinct downstream effects, offering a way to tune therapeutic outcomes by CAR selection.
The team has filed a patent through their institution’s technology office for the method of engineering CAR-astrocytes.
“Like antibody-based treatments, this strategy works best when applied early,” said co-author David M. Holtzman, MD. “But its potential advantage lies in the durability and single-dose administration that reconfigures brain cells from within.”
Future work will focus on optimizing CAR constructs to maximize amyloid clearance while preserving normal brain functions and minimizing inflammation or off-target effects. The researchers also plan to explore redirecting CAR-astrocytes to recognize tumor-specific markers, which could convert astrocytes from cleaners into tumor-targeting effectors for treating brain cancers and other central nervous system disorders.
Key Questions Answered
A: Yes. It uses the same CAR technology concept. Instead of modifying immune T cells to attack tumors, scientists modify brain-resident astrocytes to recognize and remove amyloid-beta plaques associated with Alzheimer’s.
A: Antibodies require repeated high-dose administration and can have limited brain penetration. Reprogramming cells already in the brain can provide sustained, localized clearance without repeated systemic dosing. In this study, a single treatment produced durable plaque reduction in mice.
A: These findings are preclinical. Significant additional research is needed to confirm safety, rule out unwanted inflammation or loss of normal brain functions, and to conduct clinical trials in humans.
Editorial Notes
- This article was edited by an editor at Neuroscience News.
- The full journal paper was reviewed for this summary.
- Additional context was provided by staff editors.
About this research
Author: Jessica Church
Source: Washington University School of Medicine
Contact: Jessica Church – Washington University
Image credit: Neuroscience News
Original research: “Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CARA) therapy” by Yun Chen et al., published in Science. DOI: 10.1126/science.ads3972. This study reports preclinical results in a mouse model and describes CAR designs that fuse anti-amyloid single-chain fragments to phagocytic receptor domains to enable astrocyte-mediated Aβ clearance.
Abstract
Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CARA) therapy
INTRODUCTION
Alzheimer’s disease is the leading cause of age-related dementia. Pathology progresses from extracellular amyloid-β accumulation to tauopathy within neurons and ultimately neurodegeneration. Anti-amyloid monoclonal antibodies can slow progression but face limitations including repeated dosing, a narrow therapeutic window, imaging-related risks, and dependence on specific immune signaling pathways. These constraints motivate alternative strategies.
RATIONALE
Chimeric antigen receptors can be engineered by linking anti-amyloid single-chain variable fragments to intracellular phagocytic signaling domains, creating a self-sufficient system that empowers glial cells to recognize and clear Aβ aggregates. Targeting astrocytes offers the advantage of converting an abundant, widely distributed glial population into a durable, brain-intrinsic clearance mechanism that avoids challenges of replacing microglia.
RESULTS
The team designed multiple FcRγ-independent CAR constructs that enhanced phagocytosis and Aβ degradation in vitro. Two lead CARs were delivered in vivo via systemic AAV-PHP.eB-mediated GFAP-driven expression, achieving CNS-wide astrocyte transduction. After plaque formation, single administration of either CAR reduced amyloid burden and neuritic dystrophy within three months; early delivery prevented Aβ accumulation for months. Single-nucleus RNA sequencing revealed CAR-induced astrocyte states and a shift in microglia toward more homeostatic profiles, with different CAR designs producing partially distinct effects.
CONCLUSION
This work demonstrates the feasibility of adapting phagocytic CAR technology to the central nervous system by targeting astrocytes, creating a new therapeutic axis for Alzheimer’s disease. The platform’s flexibility allows CAR signaling to be tuned to specific goals. Future optimization will aim to maximize amyloid clearance while preserving neuronal health, minimize off-target effects, and extend the approach to other cell types and CNS diseases.